MD Anderson researchers find that drug combination acts against aggressive chronic lymphocytic leukemia
- Posted: December 11, 2012
A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced responses with minor side effects in a Phase 2 clinical trial at The University of Texas MD Anderson Cancer Center.
the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.